Summary of actinic keratosis studies with imiquimod 5% cream.
Imiquimod is being investigated as a therapeutic option for the management of actinic keratosis. Three recent clinical trials have demonstrated a reasonable efficacy rate and high safety profile. 'Cycle' therapy may improve the safety profile while maintaining efficacy. 'Field' treatment with imiquimod may uncover and treat 'subclinical' actinic keratoses, which in turn may potentially result in fewer recurrences. Longer follow-up studies are required to investigate this possibility.
Tran
H
H
Department of Dermatology, St George Hospital, University of NSW, Sydney, Australia.
Chen
K
K
Shumack
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D000077271:Imiquimod; D007642:Keratosis / Q000188:drug therapy* / Q000209:etiology*; D009824:Ointments; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D009824:Ointments; D000077271:Imiquimod